Investing.com - Bicycle Therapeutics Ltd (NASDAQ: BCYC) reported third quarter EPS of $-1.26, $0.06 worse than the analyst estimate of $-1.20. Revenue for the quarter came in at $5.35M versus the consensus estimate of $12.94M.
Bicycle Therapeutics Ltd's stock price closed at $15.35. It is down -34.60% in the last 3 months and down -37.01% in the last 12 months.
Bicycle Therapeutics Ltd saw 8 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Bicycle Therapeutics Ltd's stock price’s past reactions to earnings here.
According to InvestingPro, Bicycle Therapeutics Ltd's Financial Health score is "fair performance".
Check out Bicycle Therapeutics Ltd's recent earnings performance, and Bicycle Therapeutics Ltd's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar